Kane Biotech Inc (TSE:KNE)
:KNE
Want to see TSE:KNE full AI Analyst Report?
KNE Stock Chart & Stats
C$0.03
<C$0.01(4.76%)
At close: 4:00 PM EST
C$0.03
<C$0.01(4.76%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.09
Previous CloseN/A
Volume199.87K
Average Volume (3M)112.95K
Market Cap
C$6.36M
Enterprise ValueC$7.77M
Total Cash (Recent Filing)C$901.70K
Total Debt (Recent Filing)C$2.30M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding181,856,570
10 Day Avg. Volume120,057
30 Day Avg. Volume112,955
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.69
Price to Sales (P/S)15.17
P/FCF Ratio-1.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Anti-biofilm PlatformA proprietary anti-biofilm technology addresses persistent clinical and industrial problems where alternatives are limited. The platform nature supports multiple end-markets (wound care, animal health, industrial) and licensing, creating durable product and revenue diversification opportunities if adoption scales.
Reduced Debt LevelsMaterial debt reduction improves solvency and lowers fixed financing costs, extending operational runway and reducing near-term refinancing risk. This strengthens the balance sheet foundation and supports longer-term commercialization and R&D plans if the trend continues.
Improving Cash-flow TrendA move toward less negative operating cash flow and positive free-cash-flow growth signals progress toward self-sufficiency. Sustained improvement would reduce reliance on external capital and support reinvestment in commercialization and development, improving long-term viability.
Bears Say
Persistent Net LossesConsistent net losses and deeply negative operating results erode retained capital and limit the company's ability to fund growth internally. Without sustainable profitability, the firm remains dependent on investors or lenders, constraining strategic flexibility over months to years.
Negative Shareholders' EquityNegative shareholders' equity is a structural capital weakness that increases insolvency sensitivity and restricts access to debt or favorable partner terms. It undermines financial credibility and elevates long-term refinancing and going-concern risks unless equity is restored.
Ongoing Cash Burn And Funding DependencePersistent negative operating and free cash flow means continued reliance on external financing, which can be dilutive or expensive. This chronic cash burn threatens the pace of R&D and commercialization and raises the probability of disruptive capital raises in the medium term.
KNE FAQ
What was Kane Biotech Inc’s price range in the past 12 months?
Kane Biotech Inc lowest stock price was C$0.03 and its highest was C$0.09 in the past 12 months.
What is Kane Biotech Inc’s market cap?
Kane Biotech Inc’s market cap is C$6.36M.
When is Kane Biotech Inc’s upcoming earnings report date?
Kane Biotech Inc’s upcoming earnings report date is May 21, 2026 which is in 16 days.
How were Kane Biotech Inc’s earnings last quarter?
Currently, no data Available
Is Kane Biotech Inc overvalued?
According to Wall Street analysts Kane Biotech Inc’s price is currently Overvalued.
Does Kane Biotech Inc pay dividends?
Kane Biotech Inc does not currently pay dividends.
What is Kane Biotech Inc’s EPS estimate?
Kane Biotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kane Biotech Inc have?
Kane Biotech Inc has 181,856,570 shares outstanding.
What happened to Kane Biotech Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kane Biotech Inc?
Currently, no hedge funds are holding shares in TSE:KNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
Technical Analysis
Aptose Biosciences
―
XORTX Therapeutics Inc
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---